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DEMOGRAPHICS AND QUALITY OF LIFE EFFECTS OF NORMOBARIC 
OXYGEN ON COHORT OF PATIENTS WITH RETINAL VEIN OCCLUSIONS 
ROBERT J. MINTURN 
ABSTRACT 
Purpose: This study examined the effects of normobaric oxygen in patients 
diagnosed with either a Central Retinal Vein Occlusion (CRVO) or Branched 
Retinal Vein Occlusion (BRVO) who had previously undergone treatment via 
Anti-VEGF or PRP treatment. The investigation looked into the changes in 
Macular Thickness (MT) and Visual Acuity (VA).  
Methods:  This pilot study analyzed patient data from Beth Israel Deaconess 
Medical Center (Boston, MA) that had been diagnosed with Retinal Vein 
Occlusions. The patients were brought in and given 3 hours of normobaric 
oxygen via an oxygen concentrator with imaging and vision checked both before 
and after the therapy.  
Results: Eighty-eight percent of our patients in this pilot study saw a decrease in 
macular thickness after 3-hour oxygen therapy. The mean change in Maximal 
Macular Thickness was a decrease of 7.1% which was statistically significant 
when compared to healthy eyes (p<0.001). Additionally, 44% of patients saw an 
increase in visual acuity, the primary measure of vision. Visual acuity showed a 
statistically significant change when compared to changes in healthy eyes 
(p=0.015). No statistical significance was found in the testing of contrast 
sensitivity nor intraocular pressure.  
 
 vii 
Conclusion: Our study showed improvement in central macular thickness and 
quality of life for individuals using noninvasive normobaric hyperoxia as a treatment 
for retinal vein occlusions. However, further research is needed to improve the 
impact of the study and a full randomized control trial should be implemented to 
further understand the potential impacts of a noninvasive normobaric hyperoxia 
treatment as a means to alleviate symptoms in retinal vein occlusions. In addition, 
in the future oxygen supplementation in conjunction with periodic injections of Anti-
VEGF could be investigated as a treatment regimen with potential benefits beyond 
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 In ~360 BC Aristotle published the first of his books entitled Metaphysics, 
within which was theorized that vision was the dominant sense for humans due to 
its ability to allow for distinction and classification of objects (“XXIV.I. Which of the 
five Senses is most Noble,” n.d.). Over time with the implementation of new 
technologies such as the automobile, computer, and smartphone, sight has only 
gained greater importance for functionality within society. As a result, in this study 
we wanted to look at a novel noninvasive treatment that could provide benefits to 
both the disease state and quality of life of afflicted patients.  
 
Anatomy of the Human Eye 
 The human eye is the dominant visuospatial organ in the body for humans, 
used both for orientation and identification within day to day life. Sitting within the 
orbit the eye refracts light from the surrounding world through the cornea, lens, 
and the aqueous humor onto the retina. The image that is formed on the retina is 
then communicated to the occipital lobe of the brain, thus allowing an individual to 
categorize and gain information from the image that is created.  
The eye is divided into two major divisions the anterior and the posterior 
segment. The major purpose of the anterior segment is making the necessary 
adjustments in order to focus light onto the retina for the proper formation of an 
image. The anterior segment is filled with an extracellular aqueous humor and the 
major structures are the iris, cornea, lens, and the ciliary bodies. It is further 
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subdivided into the anterior chamber (AC) and the posterior chambers (PC), 
marked by the iris. Movement of the iris controls the size of the pupil, thereby 
allowing varying levels of light into the eye based on environmental levels of light. 
The majority of the posterior segment of the eye consists of the vitreous body, a 
space filled with thick extracellular vitreous humor. Other major structures in the 
posterior segment are the retina, choroid, and optic nerve. The choroid is a dense 
network of capillaries that operates as the vasculature for the outer layers of the 
retina providing both nutrients and oxygen (Khurana, Khurana, & Khurana 
Bhawna, 2015) (“Normal vision | Children’s Hospital of Wisconsin,” n.d.). 
 
Figure 1: This illustration shows the general anatomy of the eye. The eye is separated into 
two segments the anterior segment and the posterior segment. The anterior segment 
consists of structures anterior to the lens, its primary function is the focusing of light onto 
the posterior segment. The posterior segment is posterior to the lens and has the primary 




 The retina is found posterior to the vitreous body and is a neuronal layer of 
the eye responsible for light capture and image formation. The retina is divided into 
ten layers that run in parallel; the inner limiting membrane, nerve fiber layer, 
ganglion cell layer, inner plexiform layer, inner nuclear layer, outer plexiform layer, 
outer nuclear layer, outer limiting membrane, photoreceptor layer, retinal 
pigmented epithelium, and choroid.  
 
Figure 2: The retina is composed of multiple layers of neuronal tissue depicted by this 
image. Light hits the layer in the following order; Inner Limiting Membrane (ILM), 
Ganglion Cell Layer (GCL), Inner Plexiform Layer (IPL), Inner Nuclear Layer (INL), Outer 
Plexiform Layer (OPL), Outer Nuclear Layer (ONL), Outer Limiting Membrane (OLM), and 
the photoreceptor layer. Each layer of the retina has cells specialized for their unique 
functions. Within the Photoreceptor Layer and the ONL can be found rods and cones. 
Within the OPL and INL horizontal and bipolar cells can be found. Image adapted from 




The retina has six major cell types that each have their own specialization 
for function; photoreceptors, bipolar cells, horizontal cells, amacrine cells, ganglion 
cells, and Müllerian glia. Bipolar cells have primary function of communicating 
information from the photoreceptors to the dendrites of the ganglion cells. 
Horizontal cells mediate these signals at the photoreceptor level by communicating 
laterally between photoreceptors, thereby modulating the output of information 
between photoreceptors and bipolar cells. Similarly, the amacrine cells 
communicate laterally between the bipolar cells to modulate information at the 
level of the bipolar cell to ganglion cell. Finally, ganglion cells are responsible for 
the communication of information to the optic nerve in the final step of light 
transduction within the eye (Kolb, Fernandez, & Nelson, 1995). 
Most important among the cells are the photoreceptors. There are two main 
types of photoreceptors; rods and cones, responsible for the capture of light and 
the formation of images. The photoreceptors function through the absorption of 
light, absorption of light causes a decoupling of vitamin A from rhodopsin, this 
reaction leads to the conversion of light energy into electrochemical energy. This 
electrochemical energy is subsequently communicated through the cells of the 
retina to the optic nerve, where it is carried to the occipital lobe and signal 
transduced. The two types of photoreceptor cells vary in function and quantity. 
Rods are the most prevalent type of photoreceptor, outnumbering cones in a 20:1 
fashion, and they are responsible for the capture of black and white light. In 
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contrast cones are responsible for the capture of colored light and are responsible 
for the sharpness of images.  
Within the retina there are two main areas the macula and the periphery. 
The periphery of the retina is primarily composed of rod photoreceptors, it has the 
responsibility for the peripheral vision and night vision in humans. Despite being 
approximately 5 mm in diameter the macula is the most important portion of the 
eye when it comes to image formation, it is located directly in line with the lens and 
is the desired focal point for the eye. At the center of the macula is the fovea, a 
region of the eye composed exclusively of cone cells, which has the highest 
concentration of photoreceptors and creates the sharpest image for humans 
(Laouri, Chen, Looman, & Gallagher, 2011).  
 
Retinal Imaging 
 When it comes to retinal imaging there are two main forms used: a fundus 
examination and optical coherence tomography (OCT). OCT functions by splitting 
light from a source into two beams, one called the reference arm and one called 
the sample arm. Through computer analysis of the interference between the two 
beams both axial and transverse scanning is achieved, by the reference and 
sample arm respectively, for the formation of a 3D image output. There are two 
main types of OCT, Time Domain OCT (TD-OCT) and Spectral Domain OCT (SD-
OCT). TD-OCT uses a moving mirror where as a SD-OCT uses a fixed mirror on 
the reference arm, the fixation of the mirror in SD-OCT allows for higher image 
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definition and the elimination of mechanical speed limitations that are present with 
a moving mirror (Popescu et al., 2011). For our study we used an SD-OCT due to 
the improved time of acquisition and higher image resolution.  
A fundus exam requires a physician to use an indirect ophthalmoscope or 
a slit lamp to shine a light through a patient’s dilated pupil in order to visualize the 
retina. This form of retinal evaluation allows the physician to see the entirety of the 
retina, both the periphery and the macula, and any symptoms that present on the 
surface of the retina such as areas of atrophy, microaneurysms, edema, tears, 
detachments, or traction. A fundus exam is the primary form of retinal evaluation 
for an ophthalmologist and can elucidate a large amount of information in order to 
make a differential diagnosis. 
  
Figure 3 Image of a normal fundus exam adapted from Tabandeh and Goldberg, 2009.  
 
7 
 Optical Coherence Tomography (OCT) is another form of imaging 
commonly used for both clinical and research application in ophthalmic practices. 
OCT allows for noninvasive imaging through computer interpretation of the 
scattering and reflection of light from a camera in the eye, resulting in a digital 
cross-sectional image of the retina. While there are various additional features that 
researchers have found and implemented with OCT the basics of the imaging 
technology allow us to visualize each layer of the retina and allows us to see the 






Figure 4 Image produced of a normal image taken of the macula with Optical Coherence 
Tomography. Image adapted from Sharma and Sergott, 2016. 
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Pathogenesis of Retinal Vein Occlusions 
 The retina has two major blood supplies, the retinal vessels and the 
choroidal vessels, both of which branch from the ophthalmic artery. The retinal 
arteries primarily supply the inner layers of the retina and these vessels maintain 
autoregulation. In contrast the choroidal vessels supply the inner layers of the 
retina and have little autoregulation, leading to a relatively constant flow of blood 
through the choroid. Both the Choroidal network and the retinal vessels have their 
own respective veins for drainage. In the case of the retinal vasculature conditions 
can arise in which the retinal veins get blocked, these conditions are broadly known 
as Retinal Vein Occlusions and are further subdivided into Central Retinal Vein 
Occlusions (CRVO), which has a prevalence rate of 0.2%, and Branched Retinal 
Vein Occlusions (BRVO), with a prevalence rate of 2% (Laouri et al., 2011). 
While each condition has unique presentations and their own pathogenesis 
the risk factors are common and include; Hypertension Atherosclerosis, Diabetes, 
Primary Open Angle Glaucoma, Macular Edema, or Vitreous Hemorrhage. The 
primary risk factor for a manifestation of a retinal vein occlusion is hypertension 
(Bertelsen et al., 2012). Atherosclerosis is often secondary to hypertension and is 
due to the hardening of the retinal arteries at locations where they are adjacent to 
retinal veins. As the arteries become more atherosclerotic, they induce a change 
in the retinal veins leading to the formation of blood clots in the veins, and creating 
an occlusion (Chong, 2012). Additionally, the atherosclerotic secondary risks to 
Retinal Vein Occlusions include retinal edema, vitreous hemorrhages, and rare 
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instances of secondary glaucoma. In instances where retinal edema occurs in the 
area of the macula, patients experience a drastic decrease in visual acuity  
(Tabandeh, 2009).  
 
Diabetes also has a strong correlation to the onset of Retinal Vein 
Occlusions due to the effects that diabetes has on the vasculature and the higher 
risk of atherosclerotic plaque formation. In diabetics blood vessels get damaged 
due to the higher amounts of glucose in the blood, as the constant elevation of 
glucose levels leads to hyperactivity of the polyol pathway, also known as the 
sorbitol pathway. In turn the hyperactivity of the polyol pathway leads to a depletion 
Figure 5 This image shows a branched retinal vein that has developed a sheathing 
over time, a possible long-term effect if the vein occlusion does not resolve.  Image 
adapted from Tabandeh and Goldberg, 2009. 
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of endothelial cells Dihydronicotinamide-adenine dinucleotide phosphate 
(NADPH), and subsequent damage of the endothelial lining of the microvascular 
network in patients with diabetes (Rask-Madsen & King, 2013) The damage to the 
microvascular network leads to greater microvasculature permeability, hemostasis 
and potential endothelial cell apoptosis. As a result, diabetic patients have elevated 
Figure 6 This image demonstrates the effects of diabetes on normal vasculature and 
on retinal capillaries.  In the normal vasculature diabetes leads to a higher risk of 
plaque formation. The binding of Leukocytes to the plaque leads to a higher risk of 
thrombus formation. In the retinal capillaries diabetes leads to higher rates of 
leukocyte binding, which leads to greater leakage of red blood cells and associated 
proteins. The damage to the blood vessels subsequently can lead to neovascularization 
and or apoptosis. Image adapted from Rask-Madsen and King, 2013.  
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risk factors associated with the development of occlusions due to thrombosis and 
greater risk of edema.   
 
Current Treatment Options 
 Currently the main healing agents in Retinal Vein Occlusion treatment is 
time, as both CRVOs and BRVOs eventually resolve themselves as the clot breaks 
up. However, both conditions lead to the secondary development of ME which can 
lead to retinal degeneration and a decrease in visual acuity if left untreated and 
neovascularization if very severe cases. Thus, treatment generally involves 
managing symptoms to minimize the amount of permanent damage done to the 
retina until the occlusion passes, which can take months to decades.   
The primary treatment for neovascularization is Panretinal 
Photocoagulation (PRP), an in-office procedure using an argon laser to indirectly 
decrease the number of new growing blood vessels in the periphery of the retina. 
The effectiveness of PRP ultimately lies in the destruction of highly metabolically 
active peripheral outer retinal tissue, decreasing the amount of oxygen consumed 
by the retina and subsequently decreasing the amount of Vascular Endothelial 
Growth Factor (VEGF) produced (Stefánsson, 2001). In addition, through the 
destruction of the outer retinal tissue the inner retinal layer is preserved through 
relief of hypoxia via oxygen diffusion from the choroid (Linsenmeier & Zhang, 
2017). While PRP does not work instantaneously, a course of treatment over 
several months has shown to decrease the proliferation of new blood vessels in 
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the retina through the easing of hypoxemia experienced by the inner retinal tissue. 
Potential complications of PRP include the worsening of macular edema, 
exudative retinal detachments, decreased visual field, and difficulty seeing at night 





Figure 7 Image of patient with a Central Retinal Vein Occlusion (CRVO) 
treated with Panretinal Photocoagulation (PRP) over several years. The left 
image is of the healthy right eye and the right image is of the eye with a 
diagnosis of CRVO after several years of treatment. Through PRP the outer 
retinal layer is destroyed allowing for decreased consumption of oxygen and 
allows oxygen to travel through the scarred tissue to the inner retina more 




 Another form of treatment for macular edema is the intraocular injection of 
Anti-VEGF drugs, directly delivered into the vitreous to decrease the presence of 
VEGF. There are currently three main Anti-VEGF drugs used bevacizumab, 
aflibercept and ranibizumab. Bevacizumab, known as Avastin, is the most 
commonly used and is a humanized antibody created for the binding of VEGF-A. 
Aflibercept, known as Eylea, is a recombinant VEGF binding protein that targets 
VEGF-A though direct binding. Ranibizumab, known as Lucentis, is a fragment of 
a monoclonal antibody that binds to VEGF-A (Bressler, 2017). 
 
Figure 8 In this figure the VEGF mediated pathway is diagramed. The VEGF pathway is an 
angiogenic pathway that operates via the molecule VEGF binding to a Tyrosine kinase 
receptor, leading to the initiation of a cascade pathway. At the top of the image are visual 
representations of both Avastin and Lucentis. Image adapted from Pandey, 2017. 
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History of Supplemental Oxygen 
 In a Retinal Vein Occlusion there is major concern of the tissue adjacent to 
the occlusion becoming atrophic due to hypoxia. While the actual occlusion often 
will resolve itself over time there is concern that the prolonged state of macular 
edema and hypoxia will lead to atrophy of the photoreceptors, leading to long-term 
loss of vision. In addition, the hypoxic state leads to the production of VEGF, and 
other mediators, which are the primary cause of the secondary complications of 
vein occlusions like macular edema (Linsenmeier & Zhang, 2017). Prevention of 
these secondary complications through oxygenation has the potential to decrease 
the loss of vision in patients with vein occlusions through the preservation of viable 
retinal tissue. In animal models it has been seen that in the case of retinal 
detachments the use of hyperbaric oxygen can lead to improved post repair vision 
as opposed to operations that were not treated with oxygen (Wang & Linsenmeier, 
2007). In the model of retinal detachments, it is believed that the separation of the 
inner retina from the outer retina leads to atrophy of the photoreceptors and 
decreased visual outcomes. In addition, a study done by Dr. Quan Dong Nguyen 
looked at the use of supplemental oxygen for the treatment of macular edema. The 
study found that long term oxygen therapy led to a statistically significant decrease 
in central macular thickness, with some of the individuals also having visual acuity 
improvement of greater than 2 lines (Nguyen et al., 2004). These two studies are 
the basis of the belief that macular edema and the resultant decrease in visual 
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acuity has a hypoxic component to the disease, and as a result increased oxygen 
can have benefits for those suffering from macular edema. 
 
Visual Acuity 
 Visual Acuity (VA) is the traditional method for the measuring of vision, it is 
what most people think of when they go to their optometrist or ophthalmologist, 
involving the reading of several varying letters. The most common form of visual 
acuity measure is the Snellen chart that is the most used chart in clinical settings. 
The Snellen chart ranges from 20/400-20/15 vision and is traditionally 
administered in a dark room projected onto a wall from a lamp or projector. 
However, limitations of the Snellen chart are the varying number of letters per row 
and an inconsistent decrease in the letter size decrease from line to line (Shamir, 
Friedman, Joskowicz, Mimouni, & Blumenthal, 2016). For clinical use and quick 
assessment of visual acuity the Snellen chart preforms adequately. However, as a 
Figure 9 This is a traditional Snellen chart formatted for a slide projector used to measure 
visual acuity. Of note is that each line represents a different level of visual acuity, calculated by 
the visual angle for the letters on the respective line. One shortcoming of this chart is the lack 
of intraline consistency, due to inconsistency in number of letters and size decrease in 
lettering. Image adapted from Peter Kaiser, 2009.  
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result of the limitations, there can be a large range of variability that is experienced 
for an individual patient being repeatedly tested.  
A second chart used for testing visual acuity was developed in response to 
the limitations of the Snellen chart, giving way to the Early Treatment Diabetic 
Retinopathy Study (ETDRS). The ETDRS poses distinct advantages to that of the 
Snellen in that it is not a fixed chart, allowing for ability to measure vision at various 
distances, and has enhanced sensitivity for individuals with low visual acuity. In 
addition, the ETDRS chart operates on a logarithmic scale that creates equal 
decrease in size from row to row of the chart with a consistent number of letters 
per row, thereby eliminating the shortcomings of the Snellen chart. These changes 
in the formulation of the ETDRS chart have led to greater test retest reliability for 
patients and more reliable visual acuity measures for individuals with diseases 
such as AMD and Diabetic Retinopathy (Silva et al., 2012). A study done by Dr. 
Peter Kaiser showed that the differences in such disease states can be as many 
as 10 letter difference in visual acuity for individuals with vision of <20/200, 5 letters 
for individuals with vision 20/50 to 20/200, and 4 letters for individuals with 20/20 
to 20/50 vision (Kaiser, 2009). As a result, there was an inverse relationship 
between difference between charts and visual acuity, as visual acuity worsened 
the difference between charts grew greater. While the ETDRS chart does have its 
benefits there are also shortcomings. In particular it is a larger physical chart to 
ensure consistency and it requires a minimum space of 13 feet to accurately test 
vision. These limitations have decreased its clinical applications, however, the 
 
17 
ETDRS chart is a standardized means for research due to its translation between 
studies and higher level of reliability in data (Silva et al., 2012).  
 
 
Finally, one last form of visual acuity measure is Contrast Sensitivity (CS). 
Unlike the ETDRS and the Snellen charts the Contrast Sensitivity chart outputs an 
acuity measure called the Contrast Sensitivity Function (CSF). The CSF is 
calculated by measuring contrast thresholds over four different spatial frequencies, 
expressed in cycles per degree (cpd). Through the graphical measurement of at 
all four cpds a numeric outcome is achieved which represents an individuals 
Figure 10 The image above is an adapted image of a standardized Early Treatment 
Diabetic Retinopathy Study chart. This chart differentiates in from the Snellen chart 
through a greater level of standardization intralines. Visual acuity is determined 
based on the number of letters correctly read. These alterations lead to a greater 






Contrast Sensitivity Function. The CSF is a measure of how well an individual is 
able to detect differences in gradation of black and white, which is representative 






Quality of Life 
 The majority of ophthalmic conditions are not life threatening, however they 
can have drastic impact on a patient’s independence and how they are able to live 
their life. The measurement of quality of life is data that must be gathered through 
query and conversation with the patient. The National Eye Institute- Visual 
Functioning Questionnaire- 25 (NEI-VFQ 25) was created and validated through 
the National Eye Institute for the purpose of standardization across ophthalmic 
research in regards to quality of life measures. The NEI-VFQ 25 also is 25 
questions that can be taken as a repeated measure to track the changes in quality 
of life for a patient longitudinally both during and after a treatment regimen. In 
addition, the NEI-VFQ 25 has developed several subsections that can be given for 
the purpose of tracking near vision, social functioning, independence and mental 
state (Orr et al., 2011). The NEI-VFQ is the gold standard in ophthalmology for 
measuring how an individual’s life changes longitudinally over the course of their 
treatment for ocular conditions. In ophthalmology a group of physicians led by Dr. 
Figure 11 The chart above is the CSV-1000e the same type if contrast 
sensitivity chart we used in our research. It works by patients correctly 
identifying which circle contains the vertical lines. Each lettered row represents 
a different spatial frequency, measured cycles per degree. With Row A, B, C, and 
D measuring 3, 6, 12, and 18 cpd respectively. The second image is the key and 
standardized chart used for calculating functional acuity, a measure of an 
individual’s ability to operate within daily life. This image is provided courtesy 
of Vector Vision the manufacturer of the CSV 1000e, 2018.  
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Gary Brown have conducted a series of studies that look at the correlation between 
visual acuity and quality of life, as well as have led independent studies on the 
effects of quality of life for the treatment of various ocular conditions with Anti-
VEGF treatments. In these studies they established that the standards for quality 
of life should be measured through an NEI-VFQ questionnaire and then 
subsequently look at the utility of the treatment through a standard gamble analysis 
and time-tradeoff analysis (Brown, Brown, Stein, Smiddy, & Ophthalmic Utility 
Research Study Group, 2018). 
 
MOCA Test 
 The Montreal Cognitive Assessment Test (MOCA) is a standardized rapid 
assessment of an individual’s mental capacity and function. It can be given in a 
repeated fashion to analyze whether an individual has had any changes in their 
mental faculties. The test is a short 8 question response sheet that mixes 
visuospatial, speaking, math and identification exercises. While this test is not a 
major component of our research we were interested in using it to ensure there 
were no adverse mental effects beyond the norm for patients who were treated 
with oxygen therapy. Because the treatment leads to a higher oxygen 
concentration in the blood, we wanted to ensure proper blood flow to the brain was 
maintained and that the treatment did not change blood flow drastically to the body 






Figure 12. This image contains a portion of the Montreal Cognitive Assessment test. 
These questions elucidate the various types of knowledge that MOCA tests for including; 
visuospatial, memory, identification and math. Image captured directly from “MOCA-




 This paper looks at analyzing the potential improvement in quality of life 
through the implementation of a non-invasive treatment for Retinal Vein 
Occlusions that traditionally use lifelong intraocular injections as the first line 
treatment. In this paper we will look at the decision criteria and setup of the study, 
as well as investigate the preferences and impact on the quality of life of patients 
who are being treated for ocular conditions with an underlying ischemic basis for 
the disease.  While many studies have validated the effectiveness of intraocular 
injections, primarily Anti-VEGF, as means of treatment for these conditions, few 
studies have investigated how such a course of treatment effects the patient and 
their daily lives.  
 This study aims to investigate the impact of intraocular injections on the 
quality of life of our patient cohort and investigate whether a noninvasive treatment 
that we have found to improve visual measures could also serve to increase quality 




 This study is a case series of a pre-clinical trial therapy: normobaric 
hyperoxia therapy to treat retinal vein occlusions.  All patients were diagnosed with 
a Central Retinal Vein Occlusion or a Branched Retinal Vein Occlusion at the Beth 
Israel Deaconess Medical Center in Boston, MA and had a history of prior 
treatments, including anti-VEGF injections and pan retinal photocoagulation.  
Patients with other concurrent retinal disease, significant media opacities, history 
of lung disease or smoking and recent treatment (< 3 months) were excluded.  All 
patients signed an informed consent form reviewed by BIDMC’s Institutional 
Review Board and this research adhered to all specificities outlined in the 
Tennents of Helsinki.   
 
Recruitment 
Patients were recruited through conversations with their retinal specialist.  
Recruitment generally occurred at the end of a routine clinical visit, with the 
principal investigator explaining the risks and potential benefits associated with this 
study.  Participants then signed an informed consent form and followed up for their 
study visit.   
 
Oxygen Therapy 
 The oxygen therapy consisted of 3 hours of normobaric oxygen set to 5 
liters per minute. Each patient was given oxygen from either an oxygen tank set to 
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5 liters per minute (LPM) or an Everflo Oxygen Concentrator set to 5 LPM. The 
oxygen concentrators take in normal room air and decrease the amount of nitrogen 
by implementation of a molecular sieve, creating an air mixture that is higher in 
oxygen (Phillips Respironics, USA). Patients then sit in an examination chair with 
the machine on and an oxygen mask is placed over their face. Prior to initiation of 
therapy patients were instructed to inhale and exhale normally throughout the 
course of the therapy. Most commonly patients used the time to talk with loved 
ones, read, or sleep. Upon initiation of treatment the time was marked on the 
patients chart to ensure consistency in the delivery of 3 hours of oxygen.  
 
Oxygen Trial Independence 
 In a previous study we found that each trial can be treated independently 
based on analysis by Paired Welch T-tests of our study population. We found that 
in Retinal Vein Occlusions (RVO) there was no significant difference between the 
effectiveness of each trial administered, with a p-value of .11. In addition, there 
was no significant difference between end of trial Maximal Macular Thickness 
between trials, with a p-value of .41. As a result, in our research for this study we 
treated each oxygen trial as an independent data point, and only analyzed data 







 In order to ensure both consistency and accuracy we developed a protocol 
for the imaging of patients receiving normobaric oxygen therapy. All images were 
taken on the same Heidelberg Spectralis OCT machine to ensure consistency. We 
modeled this protocol on those used in previous diabetic retinopathy and Age-
related Macular Degeneration trials. A series of images were taken both prior and 
post 3-hour normobaric oxygen therapy. In order to ensure we imaged the same 
location each time a reference image was set within the Heidelberg program. 
Included in the images were a high-quality fast raster, seven-line macular scan, 
star scan, vertical scan and horizontal scan. Data from the fast raster was 
subsequently reviewed and corrected to ensure validity of measurements. From 
the images Central Macular Thickness (CMT) was recorded and the Maximum 
Macular Thickness (MMT) within the eye was located and data was recorded. CMT 
was acquired due to its correlation to visual acuity, while MMT was acquired due 
to swelling also occurring in the periphery. Through both pre and post-therapy 
imaging we were able to create a change map demonstrating the increase or 
decrease in macular thickness over the course of the 3 hours. 
 
Visual Measures  
In addition to visual imaging we checked both visual acuity with an ETDRS 
chart and a contrast sensitivity chart. Patients were brought into the same room in 
Beth Israel Deaconess both before and after oxygen therapy was administered. In 
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this room patients had vision checked first via the ETDRS vision chart set at a 
distance of 13 feet, if vision was <20/200 the chart was moved to 5 feet to gauge 
vision. Patients were then asked to read the letters on the chart to the best of their 
ability beginning at the 20/200 level and moving progressively down the chart until 
they missed majority of the letters on a line, being 3 or more letters. As a result, 
vision was noted in the manner of the best line achieved with the potential of +2, 
representing 2 letters on the subsequent line, or -2, representing missing two on 
that line. Vision was checked as best corrected vision first and subsequently 
checked with pinholes in order to account for any refractive error, or absence of 
glasses.  
We then converted visual acuity measures according to the LogMAR scale 
in order to standardize the comparison of multiple measurements at once. Visual 
acuity taken form the ETDRS measurements was converted into loMAR units in 
order to compare pre-oxygen therapy and post-oxygen therapy. For the conversion 
of visual acuity we used the following equation:  









Table 1. Conversion Between Vision Acuity in Feet and LogMAR Score  
Snellen Visual Acuity (Feet) LogMAR 
Light perception (LP) 2.60 
Hand motions (HM) 2.30 













*Table adapted from review done in Kaiser, 2009.  
 
After ETDRS vision was checked patients were given a tutorial on contrast 
sensitivity with subsequent vision check via the CSV-1000e set at a distance of 8 
feet. First the CSV-1000e was turned on, then patients were asked whether they 
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were able to distinguish the vertical lines underneath the letter of the first line. If 
they answered yes then vision for that line was checked by asking the patient each 
number and if they saw the same pattern in the top circle, bottom circle, or neither. 
Patients proceeded until they got an answer incorrect or no longer were able to 
see the vertical lines, at which point the researcher would mark the furthest point 
the patient reached. If there was concern about a patient guessing or not having 
reached a similar visual level from row to row then the patient was asked to repeat 
a row but in reverse. This measure was instituted to decrease the likelihood of 
chance in the testing process (Kaiser, 2009).   
 
Quality of Life Measures 
 In order to gain a greater understanding of how our treatment effects 
patients and their day to day life we chose to implement several measures of 
quality of life data gathering. During the patient’s time in our waiting room we 
worked with them to administer an electronic version of the NEI-VFQ 25. This 
electronic version allowed for a streamlining of data collection and buy being 
guided we ensured patients understood the questions to the best of their ability. 
(Awdeh et al., 2010) 
 While a secondary thought we also had some concerns about changes in 
mental states with a treatment that could affect blood flow to various major organs. 
As a result, we would like to monitor the mental capacities of patients longitudinally 
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to continue gathering data as to if there is any correlation between brain activity 
and increase levels of oxygen in the blood.  
In order to accurately calculate the effect of a noninvasive treatment versus 
the current gold standards of treatment we asked patients to answer a series of 
questions in order to calculate a utility score for each of the treatment options. The 
current treatment options of PRP and Anti-VEGF treatments both have in clinic 
visits with potential associated risks such as infection and pain. In contrast the 
noninvasive treatment regimen has the potential of in clinic visits with relatively few 
to no associated risks. In order to calculate a utility score, we chose to use the 
ophthalmic standard previously used by Dr. Brown and others including the time 
trade off method and standard gamble method. Both questionnaires were given to 
patients during their wait time while on oxygen.  
 
 Statistical Analysis 
 Statistical Analysis was preformed through a two-tailed Welch t-test for both 
best-corrected visual acuity (BCVA) and maximal macular thickness (MMT) in the 
RVO patients. In addition, an analysis of the quality of life measures was analyzed 
through a regression model.  Statistical analysis was considered to be significant 




 After administering 102 normobaric oxygen trials over the course of six 
months, data was reviewed and classified by disease state, extent of designated 
disease and visual acuity. From this data we analyzed 21 cases of Retinal Vein 
Occlusion which presented with minimal ocular opacity, no concurrent retinal 
diseases, initial maximal macular thickness (MMT) of less than 350 microns, and 
no intravitreal injections within 3 months prior to oxygen therapy. In addition, 13 of 
those individuals presented with a healthy eye upon initiation of the normobaric 
hyperoxia treatment. Our data was split relatively equally between men (57%) and 
women (43%), with no statistically significant difference. There was a statistical 
difference between eye of onset, however, this is explained by the smaller sample 
size of the pilot study and that retinal vein occlusions usually only effect one eye 
(x2=0.03). In addition, our population was predominantly white (57%), with 
Hispanics making up the second largest portion of our population (38%). These 
numbers are not representative of historical demographic data for presentation of 
retinal vein occlusions, and we hope in a larger study to have a more diverse 








Table 2. Demographics of Patient Population for Pilot Study 




Age 73.7 11.4 
  
Sex 















Time Since Diagnosis (Months) 49.14 49.02 
  
Effected Eye 
    
Right eye (OD) 
  
14 67 






























Hx of Smoking 















Prior Anti-VEGF Injections 9.4 7.7 
  
Time Since Injections 10.5 20.31 
  
Prior Surgeries 0.6 1.1 
  
Prior PPV 0 0 
  




4.6 2.7     
*Data obtained from Beth Israel Deaconess Medical Center between July 2018 






For the Maximal Macular Thickness (MMT) we found the point with the most 
macular swelling via OCT. Based on that point, we calculated the change of the 
central subfield, measuring 1 millimeter in diameter, surrounding the location of 
MMT as a percentage change. Our hypothesis was that these changes in the 
anatomy of the retina would lead to improvement in vision. We found that 
individuals with retinal vein occlusions on average had a decrease of 7.1% at the 
point of maximal swelling after 3 hour treatment with normobaric oxygen, this data 
was statistically significant when compared to both healthy eyes treated (Welch’s 
paired t test, p<0.001) and untreated retinal vein occlusions observed over 3 hours 
(Welch’s paired t test , p<0.001). In addition, Central Macular Thickness decreased 
a lesser amount of 4.6%, however, this was still statistically significant when 
compared to healthy eyes (Welch’s paired t test, p<0.001). Healthy eyes treated 
with oxygen therapy for 3 hours had insignificant changes in macular thickness 
when compared to untreated healthy eyes over the same period of time.  
Table 3. Results of Macular Thickness from 3 Hour Hyperoxia Trial 
  Mean 95% CI P Value 
Before Therapy 
   
   Central Macular Thickness (μ) 455.80 (407.2, 504.4) - 
   Maximal Macular Thickness (μ) 511.2 (467.0, 555.4) - 
After Therapy 
   
   Central Macular Thickness (μ) 434.4 (428.0, 440.8) - 
   Maximal Macular Thickness (μ) 475.9 (468.6, 483.2) - 
Anatomical Changes 
   
   Percent Change MMT (%) -7.1 (-5.34, -8.06) <0.001 
LogMAR Visual Acuity 
Changes**  




*Data obtained via image analysis with Heidelberg Spectralis Optical Coherence 
Tomography 
**Data obtained via visual testing with ETDRS chart and alreted to LogMAR for 
standardization 
***Data obtained from Beth Israel Deaconess Medical Center between July 2018 






Figure 13: Change in Maximum Macular Thickening after Normobaric Hyperoxia Treatment 
by Disease. A 3-hour session of NBH resulted in decreased MMT (mean 7.1%, t34=9.63 
P<.001) and CMT (mean 4.6%, t37=6.90, P<.001) when compared to untreated eyes with 
RVO measured over the same time frame or their healthy other eye (t36=-9.60, P<.001; t36=-
6.72, P<.001).  Twenty-seven out of 28 patients receiving their first session of NBH for RVO 
saw a significant reduction when compared to controls (Untreated RVO 95% CI -0.50 to 
0.77).  BRVO and CRVO did not differ significantly if MMT (t15=0.50, P=.63) or CMT 










 Visual acuity testing conducted both before and after administration of 3 
hour normobaric hyperoxia demonstrated a significant change, as measured by 
visual improvement of 5 letters or more. Seven (44%) of our patients experienced 
a statistically significant change in their visual acuity, while one patient (6%) 
experienced a decrease greater than one letter, represented in figure 14. Based 
on a Welch paired T test with 14 degrees of freedom we found that there was no 
significant difference between visual changes in Central Retinal Vein Occlusions 
and Branched Retinal Vein Occlusions.  
 
Figure 14: Change in ETDRS Visual Acuity by Disease. Sixteen patients had vision in our 
inclusion range on presentation, with an average increase of +0.04 LogMAR (2.4 ETDRS 
letters, t15=2.76, P=.015).  Of these, 7 (44%) experienced an improvement of at least 5 
letters, the commonly held threshold for significance on the ETDRS chart.  There was no 
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difference in improvement by condition (t14=-0.20, P=.84). Data adapted from Beth Israel 
Deaconess Medical Center, 2019. 
 
Quality of Life Measures 
  
 Due to restrictions in our Institutional Review Board for Quality Improvement 
and changes in the institutional review process we were unable to gather data 
within our patient population. In future studies we continue to strive to better 
understand the full implications of using a noninvasive treatment for retinal vein 
occlusions treatment through measures including; National Eye Institute-Visual 
Function Questionnaire 25 (NEI-VFQ25), standard gamble method, trade-off 







 Retinal vein occlusions (RVO) are spontaneous occurrences affecting 
roughly 16 million individuals. The manifestation of retinal vein occlusions is the 
result of thrombosis due to atherosclerotic plaque formation, and individuals with 
hypertension and diabetes are at higher risk for developing retinal vein occlusions 
due to the associated effects on the vasculature. The condition presents both as 
occlusions in the branched vessels (BRVO) of the retina and the central vessels 
(CRVO), with greater loss of visual acuity in individuals who have experienced a 
CRVO. With no available treatment for RVOs, physicians are left to treat the 
associated symptoms in order to best maintain vision for patients. Treatments 
include multiple panretinal photocoagulation treatments and monthly intravitreal 
Anti-VEGF injections.   
Of our 21 patients we administered 34 treatments of 3 hour normobaric 
hyperoxia for treatment of a branched retinal vein occlusion (BRVO) or central 
retinal vein occlusion (CRVO). Additionally, we administered 22 treatments of 3 
hour normobaric hyperoxia to 13 patients whose non-RVO eye was deemed 
healthy. Of the healthy eyes we found that one eye developed dry age-related 
macular degeneration and one eye developed proliferative diabetic retinopathy, at 
which point any subsequent trials were excluded from the healthy pool. Our 
median patient age was 73.7 years old. Our patient population was 57.15% male 
and 42.85% female. Ethnically our population was predominantly White, 57.14% 
with individuals of Hispanic ethnicity comprising of 38.09% and Asian ethnicity 
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4.76%. The limited ethnic representation in our study is one point of inquiry that 
could limit the impact of the study, and points to a need for further research in order 
to increase the implications of our work.  
 
Prior to treatment patients had a mean maximal macular thickness (MMT) 
of 511.23 microns with a mean central macular thickness (CMT) of 468.58 microns. 
Post-treatment for 3 hours with normobaric oxygen patients saw a mean decrease 
in MMT of 35.52 microns and a decrease in CMT of 21.24 microns. As a result, we 
saw a 7.1% decrease in MMT post-oxygen therapy, when analyzed with a Welch 
paired T-test with 34 degrees of freedom we found statistical significance with a P-
value of less than 0.001. This is suggestive of a strong correlation between 
decreased macular thickness post treatment with oxygen for 3 hours. In contrast 
healthy eyes saw a mean decrease of 0.4% in MMT post-oxygen therapy. In 
addition, 95% of our trials saw a decrease in MMT while 88% of trials saw a 
decrease in CMT.  
In addition, we saw a statistically significant change in visual acuity which 
increased on average 5.1 letters (test P<0.05) for individuals after treatment with 
oxygen therapy. This is in line with our hypothesis that decreasing the physiological 
manifestations of retinal vein occlusions, primarily macular swelling, will lead to 
visual improvement. In future studies we would like to expand upon this data by 
further adding a quality of life longitudinal measure to better understand how this 
visual acuity improvement effects patient’s daily life.  
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While we were unable to obtain a full spectrum of quality of life data quality 
of life data, we believe that future studies will demonstrate positive effects on 
quality of life due to the decreased burden of patients traveling to the office for 
intravitreal injections, decreased anxiety of needle placement in close proximity to 
the eye, and simplicity of the noninvasive treatment option.  
 
 
Confounding Variables  
 Because this was a pilot study, the study was limited by the number of 
participants and limited amount of data. Furthermore, while majority of patients 
were treated using two standardized Phillips everflo oxygen concentrators, there 
were instances in which oxygen tanks were used rather than the concentrators 
due to limited quantity of equipment. While the difference between the concentrator 
and oxygen tank are relatively insignificant in a full clinical trial all potential sources 
of variation should be eliminated to decrease potential impact on the results. In 
addition, while we did see slight increase in visual acuity, we discovered at the end 
of the trial that for some patients the flow of oxygen dried out the surface of the 
eye. As a result, in future research lubricating eyedrops prior to visual acuity testing 
should alleviate any potential impact corneal drying could have posed on our 
measures of visual acuity (Benítez-Del-Castillo et al., 2017). Finally, all diagnostic 
decisions were made by a single retinal surgeon, and a larger diversity of opinions 
with a standardized selection criterion could increase both the population of the 





In this project we looked at the potential changes in quality of life for patients 
with retinal vein occlusions when treated with a noninvasive treatment regimen of 
normobaric oxygen with minimal office visits as opposed to monthly intraocular 
injections. Our study showed improvement in central macular thickness and quality 
of life for individuals using noninvasive normobaric hyperoxia as a treatment for 
retinal vein occlusions. However, further research is needed to improve the impact 
of the study and a full randomized control trial should be implemented to further 
understand the potential impacts of a noninvasive normobaric hyperoxia treatment 
as a means to alleviate symptoms in retinal vein occlusions. From a full 
randomized control trial larger amounts of data could be obtained, providing a 
better understanding as to whether our findings have universal implications moving 
forward. In addition, in the future oxygen supplementation in conjunction with 
periodic injections of Anti-VEGF could be investigated as a treatment regimen with 
potential benefits beyond individual therapy.  
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 In conclusion, we have demonstrated that treatment of retinal vein 
occlusions with short-term oxygen supplementation can be beneficial in 
decreasing macular swelling and increasing visual acuity. We find that increasing 
oxygen delivery to the inner retina through oxygen supplementation decreases 
symptoms of retinal vein occlusion, which suggest that there is an ischemic 
component to retinal vein occlusions for which oxygen therapy can serve as a 
viable treatment option. Furthermore, future research is still needed to fully 
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